Stock Traders Buy Large Volume of Call Options on Insmed (NASDAQ:INSM)

Insmed, Inc. (NASDAQ:INSM) was the recipient of unusually large options trading activity on Thursday. Investors acquired 6,582 call options on the company. This is an increase of 78% compared to the typical volume of 3,690 call options.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on INSM. Cowen set a $241.00 price objective on Insmed in a research note on Thursday. Jefferies Financial Group set a $269.00 price objective on shares of Insmed in a research report on Wednesday, December 10th. Guggenheim reduced their target price on shares of Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday. UBS Group upped their price target on shares of Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Mizuho set a $212.00 price target on shares of Insmed in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $203.82.

Insmed Stock Performance

Shares of NASDAQ:INSM traded down $31.29 on Thursday, reaching $167.17. 4,342,135 shares of the company’s stock were exchanged, compared to its average volume of 2,682,920. Insmed has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a fifty day moving average of $187.37 and a 200-day moving average of $142.14. The company has a market capitalization of $35.65 billion, a price-to-earnings ratio of -26.64 and a beta of 1.01. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company’s quarterly revenue was up 52.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.27) earnings per share. On average, research analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $194.00, for a total value of $5,820,000.00. Following the sale, the insider owned 36,461 shares of the company’s stock, valued at $7,073,434. The trade was a 45.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Michael Alexander Smith sold 27,130 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the sale, the insider directly owned 54,902 shares in the company, valued at $10,089,889.56. This trade represents a 33.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 147,130 shares of company stock worth $28,480,051 in the last 90 days. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. CIBC Private Wealth Group LLC raised its stake in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in Insmed during the third quarter worth about $29,000. SBI Securities Co. Ltd. increased its holdings in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in shares of Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 81 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of Insmed by 169.7% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 151 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.